| 
					| Título : | Gelatin tannate for acute diarrhoea and gastroenteritis in children: a systematic review and meta-analysis |  
					| Tipo de documento : | documento electrónico |  
					| Autores : | Laura Fernanda Niño Serna, |  
					| Fecha de publicación : | 2020 |  
					| Títulos uniformes : | Archives of Disease in Childhood 
 |  
					| Idioma : | Inglés (eng) |  
					| Palabras clave : | Children  diarrhoea  gastroenteritis  gelatin  meta-analysis  systematic review  tannate |  
					| Resumen : | Objective: To determine the effectiveness and safety of gelatin tannate (GT) for reducing the duration of the acute diarrhoea and gastroenteritis (ADG) in children. Design: Systematic review and meta-analysis. Data sources: MEDLINE, Embase, CINAHL, Cochrane Central Register of Controlled Trials, LILACS and grey literature, published from inception to October 2018. No language restrictions. Eligibility criteria for selecting studies: Randomised controlled trials in children with ADG, comparing GT with placebo. Results: Of 797 titles identified, we included three studies (276 children). We performed a random effects model meta-analysis for the main outcome (diarrhoea duration). We did not find significant differences between GT and placebo for diarrhoea duration (mean difference (MD)=−15.85 hours; 95% CI −42.24 to 14.82, I2=92%; three studies), stool frequency at day 2 (MD=0.11 stools/day; 95% CI −0.39 to 0.62: I2=26%; two studies), diarrhoea at day 3 (risk ratio [RR]=0.46; 95% CI 0.06 to 3.47: I2=73%; two studies), vomiting (RR=1.31; 95% CI 0.95 to 1.80: I2=0%; two studies) or adverse events (RR=0.86; 95% CI 0.27 to 2.66: I2=0%; two studies). Most common adverse events included abdominal pain and nausea. Conclusion: The effect of GT was no different to placebo for mean diarrhoea duration (low certainty on the evidence) and stool frequency at day 2 (high certainty) and for the presence of diarrhoea at day 3 (very low certainty) of vomiting (moderate certainty) and of adverse events (low certainty). |  
					| Mención de responsabilidad : | Ivan D Florez, Javier M Sierra, Laura F Niño-Serna |  
					| Referencia : | Arch Dis Child. 2020 Feb;105(2):141-146. |  
					| DOI (Digital Object Identifier) : | 10.1136/archdischild-2018-316385 |  
					| PMID : | 31272969 |  
					| En línea : | https://adc.bmj.com/content/early/2019/07/04/archdischild-2018-316385 |  
					| Enlace permanente : | https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis | 
Gelatin tannate for acute diarrhoea and gastroenteritis in children: a systematic review and meta-analysis [documento electrónico] / Laura Fernanda Niño Serna ,  . - 2020.Obra  :  Archives of Disease in ChildhoodIdioma  : Inglés (eng ) 
					| Palabras clave : | Children  diarrhoea  gastroenteritis  gelatin  meta-analysis  systematic review  tannate |  
					| Resumen : | Objective: To determine the effectiveness and safety of gelatin tannate (GT) for reducing the duration of the acute diarrhoea and gastroenteritis (ADG) in children. Design: Systematic review and meta-analysis. Data sources: MEDLINE, Embase, CINAHL, Cochrane Central Register of Controlled Trials, LILACS and grey literature, published from inception to October 2018. No language restrictions. Eligibility criteria for selecting studies: Randomised controlled trials in children with ADG, comparing GT with placebo. Results: Of 797 titles identified, we included three studies (276 children). We performed a random effects model meta-analysis for the main outcome (diarrhoea duration). We did not find significant differences between GT and placebo for diarrhoea duration (mean difference (MD)=−15.85 hours; 95% CI −42.24 to 14.82, I2=92%; three studies), stool frequency at day 2 (MD=0.11 stools/day; 95% CI −0.39 to 0.62: I2=26%; two studies), diarrhoea at day 3 (risk ratio [RR]=0.46; 95% CI 0.06 to 3.47: I2=73%; two studies), vomiting (RR=1.31; 95% CI 0.95 to 1.80: I2=0%; two studies) or adverse events (RR=0.86; 95% CI 0.27 to 2.66: I2=0%; two studies). Most common adverse events included abdominal pain and nausea. Conclusion: The effect of GT was no different to placebo for mean diarrhoea duration (low certainty on the evidence) and stool frequency at day 2 (high certainty) and for the presence of diarrhoea at day 3 (very low certainty) of vomiting (moderate certainty) and of adverse events (low certainty). |  
					| Mención de responsabilidad : | Ivan D Florez, Javier M Sierra, Laura F Niño-Serna |  
					| Referencia : | Arch Dis Child. 2020 Feb;105(2):141-146. |  
					| DOI (Digital Object Identifier) : | 10.1136/archdischild-2018-316385 |  
					| PMID : | 31272969 |  
					| En línea : | https://adc.bmj.com/content/early/2019/07/04/archdischild-2018-316385 |  
					| Enlace permanente : | https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis | 
 |  |